Showing 2841-2850 of 3039 results for "".
- Fight For Sight and Prevent Blindness Announce Call for Entries for the 2020 Joanne Angle Public Health Awardhttps://modernod.com/news/fight-for-sight-and-prevent-blindness-announce-call-for-entries-for-the-2020-joanne-angle-public-health-award/2476933/National non-profit organizations Fight for Sight and Prevent Blindness are announcing a call for applications for the Joanne Angle Public Health Award, a $25,000 grant to support a public health research project seeking to put an end to unnecessary vision loss. The award was named for Ms
- Topline Results From Phase 2 Trial Show Nicox’s Glaucoma Drug Candidate NCX 470 Meets Primary Endpointhttps://modernod.com/news/topline-results-from-phase-2-trial-show-nicoxs-glaucoma-drug-candidate-ncx-470-meets-primary-endpoint/2476931/Nicox SA announced positive topline results from its US multicenter, Dolomites dose-response phase 2 clinical trial evaluating investigational NCX 470, a novel second-generation nitric oxide (NO)-donating bimatoprost analog, compared to latanoprost ophthalmic solution 0.005% in 433 patients with
- EyePoint Pharmaceuticals Announces Yutiq Presentations at AAO Annual Meetinghttps://modernod.com/news/eyepoint-pharmaceuticals-announces-yutiq-presentations-at-aao-annual-meeting/2476921/EyePoint Pharmaceuticals announced that two abstracts supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year microinsert for chronic, noninfectious uveitis affecting the posterior segment of the eye have been accepted for presentation at the American Aca
- Vertical Pharmaceuticals Announces Submission of New Drug Application for RVL-1201https://modernod.com/news/vertical-pharmaceuticals-announces-submission-of-new-drug-application-for-rvl-1201/2476894/Vertical Pharmaceuticals, a subsidiary of Osmotica Pharmaceuticals, announced the submission of a new drug application (NDA) to the FDA for approval of RVL-1201 (RVL) for the treatment of acquired blepharoptosis (droopy eyelid). RVL is a novel, once-daily ophthalmic formulation of oxymeta
- RightEye Releases Fully Commercialized Version of EyeQ Trainer Oculomotor Exercise Programhttps://modernod.com/news/righteye-releases-fully-commercialized-version-of-eyeq-trainer-oculomotor-exercise-program/2476892/RightEye has released its fully commercialized version of EyeQ Trainer, an oculomotor exercise program. Paired with its suite of EyeQ Tests, RightEye now offers a complete solution for addressing functional vision impairments faced by millions of Americans. The product will showcase at Vis
- Johnson & Johnson Vision to Launch Tecnis Synergy IOL and Showcase Latest Clinical Data at ESCRShttps://modernod.com/news/johnson-johnson-vision-showcases-latest-clinical-data-and-eye-care-solutions-at-escrs-2/2476873/Johnson & Johnson Vision will highlight key clinical data and the latest solutions in its growing portfolio of innovative products designed to improve vision care across generations at the upcoming European Society of Cataract and Refractive Surgeons (ESCRS) 2019 Annual Meeting in Paris, Fran
- MicroPulse Transscleral Laser Therapy Will be Discussed in Various Presentations and Educational Events at ESCRShttps://modernod.com/news/micropulse-transscleral-laser-therapy-will-be-discussed-in-various-presentations-and-educational-events-at-escrs/2476872/Iridex announced that its patented MicroPulse laser therapy will be featured prominently in research presented at the 2019 European Society of Cataract & Refractive Surgeons (ESCRS) meeting, to be held in Paris, France. MicroPulse Transscleral Laser Therapy (TLT) is a non-incisional, laser-ba
- Macular Degeneration Conference Series in the Spotlighthttps://modernod.com/news/macular-degeneration-conference-series-in-the-spotlight/2476865/Part of the 2019 Macular Degeneration Association Educational Conference Series will take place on Saturday, September 21, at the Doubletree Chicago North Shore Conference Center Skokie, Illinois. The conference, “Eyes on Sight,” is aimed to deliver the most up-to-date research regarding t
- EyePoint Pharmaceuticals Announces Data Highlighting Yutiq to be Presented at Retina Society Scientific Meetinghttps://modernod.com/news/eyepoint-pharmaceuticals-announces-data-highlighting-yutiq-to-be-presented-at-retina-society-scientific-meeting/2476859/EyePoint Pharmaceuticals announced that two abstracts supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for chronic, noninfectious uveitis affecting the posterior segment of the eye have been accepted for two oral presentations at the 5
- Allergan and Molecular Partners Announce Acceptance of FDA BLA for Abicipar Pegol in Patients With Wet AMDhttps://modernod.com/news/allergan-and-molecular-partners-announce-acceptance-of-fda-biologics-license-application-for-abicipar-pegol-in-patients-with-wet-amd/2479537/Allergan and Molecular Partners announced that the FDA has accepted a biologics license application (BLA) and the European Medicines Agency (EMA) has validated a marketing authorization application (MAA) for Abicipar pegol, a novel, investigational DARPin therapy in patients with wet age-related